Neurodevelopmental Disorders

BARCELONA, Spain, June 10, 2026 CONNECTA Therapeutics announced the initiation of a Phase IIa clinical trial evaluating CTH120, its...

NEW YORK, NY, May 4, 2026 GRIN Therapeutics, Inc. has announced the initiation of its pivotal Phase 3 Beeline...

Child-Friendly MB-204 Formulation Targets Neuro Disorders – February 18, 2026 | Calgary, Alberta Marvel Biosciences Corp. has secured advisory...